Sales and marketing expenses were $6.7 million for Q1 2020, compared to $3.8 million for the same period in 2025, an increase of $2.9 million or 75%. This increase was due primarily to additional personal cost of $1.9 million and increase in travel costs of $0.5 million, resulting from the expansion of our clinical and sales teams due to the IRIS integration, as well as additional amortization expense of acquired intangible assets of $0.2 million.

May 13, 2026 / receipt

Sales and marketing expenses were $6.7 million for Q1 2020, compared to $3.8 million for the same period in 2025, an increase of $2.9 million or 75%. This increase was due primarily to additional personal cost of $1.9 million and increase in travel costs of $0.5 million, resulting from the expansion of our clinical and sales teams due to the IRIS integration, as well as additional amortization expense of acquired intangible assets of $0.2 million.

May 13, 2026 / receipt, needs a key / Danilo D'Alessandro, CFO | earnings call 2026-05-13 | transcript 5642d319-240a-4ff9-b82b-cb3616ca9dcf | chars 6746-7197 | segment 6

So those are the types of things you do, you know, multiply that times 10 or 15 different opportunities with redundant vendors, with the ability to have some sort of negotiating power with our vendors of just raw materials. putting more and more products through our factory, and then even on the sales and marketing side to be able to have our clinicals travel less because the volume has increased across our portfolio in different cities, you know, with gas prices where they are and travel expenses where they are. That's a very, very meaningful part of the strategy, too, that doesn't hit our gross margin, but it's definitely going to help us on the sell-ex side of things.

May 13, 2026 / receipt, needs a key / Joe Burnett, CEO | earnings call 2026-05-13 | transcript 5642d319-240a-4ff9-b82b-cb3616ca9dcf | chars 26142-26821 | segment 26

This increase was due to higher personal costs, including share-based compensation expense of $1.4 million, resulting from increases in headcount in our clinical team, as well as increased costs of $0.9 million due to the consolidation of ERAS, partial offset by decreased marketing costs of $0.2 million and decreased travel costs of $0.2 million.

Mar 17, 2026 / receipt, needs a key / Danilo D'Alessandro, CFO | earnings call 2026-03-17 | transcript 8f491f99-4fcf-4e44-8e55-772f0b8c7b6d | chars 9062-9410 | segment 8

Sales and marketing expenses were $14.5 million for the year 2024 compared to $12.6 million for the same year, for the same period in 2023, an increase of $1.9 million or 15%. This increase was primarily due to higher personal costs, including share-based compensation expense, of $1.6 million, resulting from increases in headcount in our clinical team, increases in travel expenses of $0.4 million, partially offset by $0.1 million in other marketing activities.

Feb 26, 2025 / receipt, needs a key / Danilo, CFO | earnings call 2025-02-26 | transcript d7baa2af-77e3-4e61-ba84-33ba08e842fb | chars 9717-10181 | segment 9

This increase was due to additional personal costs and travel expenses as we expand our commercial reach as we execute on our new product launches and prepare for increased procedural volume.

Aug 7, 2024 / receipt, needs a key / Danilo, CFO | earnings call 2024-08-07 | transcript f86586d9-87ba-4d1a-a35c-5d39e86f5ec9 | chars 8550-8741 | segment 8

This increase was due primarily to additional personnel costs, including share-based compensation, resulting from increases in headcount as well as increases in travel costs as we expanded our product and service offering.

May 7, 2024 / receipt, needs a key / Joe Burnett, CEO | earnings call 2024-05-07 | transcript 402e0aad-c974-4dfc-8bab-0715d1455f16 | chars 5396-5618 | segment 5

One is the redundant space and facility that we have relative to our prior Irvine facility and the new Carlsbad facility. So bringing Carlsbad up, having some certain construction, but also having redundancy and travel between the sites and things like that while making the same number of products, that is obviously going to impact gross margins, and we certainly saw that in the quarter.

Aug 8, 2023 / receipt, needs a key / CEO, CEO | earnings call 2023-08-08 | transcript 71abc2a6-2dc8-4636-b979-c06caf64bd60 | chars 32384-32774 | segment 32

Sales and marketing expenses were 2.9 million for the first quarter compared to 2 million for the same period in 2022, an increase of 0.9 million or 45%. This increase was due primarily to additional personnel costs, including share-based compensation resulting from increases in headcount, of $0.8 million, as well as increases in travel costs of $0.1 million.

May 11, 2023 / receipt, needs a key / Danila, other | earnings call 2023-05-11 | transcript 849132a8-9553-41e1-b49d-b719672d82e9 | chars 1724-2085 | segment 1

This increase was primarily due to increases in personal costs, including share-based compensation expense of $1.5 million, resulting from increases in headcount in our clinical and marketing teams, increases in travel expenses of $0.3 million, and increases in marketing activities of $0.2 million.

Mar 1, 2023 / receipt, needs a key / Danilo De Alessandro, CFO | earnings call 2023-03-01 | transcript 34436d66-0674-4de9-a590-5acd6d3cb312 | chars 4860-5159 | segment 5

This increase was due primarily to additional personnel costs resulting from an increase in headcount of $0.2 million as we expanded our clinical team, as well as increases in travel costs of $0.1 million.

Nov 8, 2022 / receipt, needs a key / Danilo, CFO | earnings call 2022-11-08 | transcript 51f19ca3-31d6-4bab-bd66-1ce8159e1e7c | chars 5329-5534 | segment 5

Additionally, our travel costs and marketing activities increased 0.1 million each in the quarter, General administrative expenses were $3 million in Q2 compared to $2 million for the same period in 2021, an increase of $1 million, or 51%.

Aug 9, 2022 / receipt, needs a key / Danilo D'Alessandro, CFO | earnings call 2022-08-09 | transcript 0aa7b8e1-994c-41e5-be18-e767c02d828f | chars 5592-5831 | segment 5

Finally, the geopolitical issues in Europe are very difficult to predict relative to travel, new installations, material costs, hospital overcrowding, et cetera. So that risk is really not understood at this point and therefore not included in that guidance.

May 11, 2022 / receipt, needs a key / CEO, CEO | earnings call 2022-05-11 | transcript d72cad1c-e024-460d-9cdc-c2b3ca8c310a | chars 13216-13474 | segment 13

IRRAflow ACQUISITION

ir_statement / Sep 15, 2026 / receipt

OPERATING ROOM EXPANSION

ir_statement / Sep 15, 2026 / receipt

PRECLINICAL EXPANSION

ir_statement / Sep 15, 2026 / receipt

PRISM LASER THERAPY EXPANSION

ir_statement / Sep 15, 2026 / receipt

Expand Existing Portfolio Into Multiple New Indications

ir_statement / Sep 15, 2026 / receipt

Expand into the Operating Room w/ 3.0 Software, SmartFrame Duet, and Robotics

ir_statement / Sep 15, 2026 / receipt

Expand Neuro Pre-Clinical CRO Services Portfolio and Capacity including larger GLP Study Capability

ir_statement / Sep 15, 2026 / receipt

Expand Partnerships to Include Co-Development, Commercial Pricing, Drug Clinical Milestones & Royalty Based Agreements

ir_statement / Sep 15, 2026 / receipt